Mattson Financial Services LLC Takes Position in Astrazeneca Plc $AZN

Mattson Financial Services LLC purchased a new position in Astrazeneca Plc (NYSE:AZN) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 11,603 shares of the company’s stock, valued at approximately $2,036,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Triumph Capital Management acquired a new stake in Astrazeneca during the 3rd quarter valued at approximately $25,000. Bangor Savings Bank raised its position in shares of Astrazeneca by 102.7% in the 4th quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after purchasing an additional 154 shares in the last quarter. Eagle Bay Advisors LLC purchased a new position in shares of Astrazeneca during the 4th quarter valued at approximately $30,000. YANKCOM Partnership acquired a new stake in shares of Astrazeneca during the fourth quarter worth approximately $31,000. Finally, TFC Financial Management Inc. grew its position in shares of Astrazeneca by 3,350.0% during the fourth quarter. TFC Financial Management Inc. now owns 345 shares of the company’s stock worth $32,000 after buying an additional 335 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on AZN. Morgan Stanley reaffirmed an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. Jefferies Financial Group reissued a “buy” rating on shares of Astrazeneca in a report on Tuesday. Barclays reissued a “buy” rating on shares of Astrazeneca in a research report on Monday, June 1st. UBS Group reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Friday, April 10th. Finally, Wall Street Zen raised Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Twelve analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Astrazeneca has a consensus rating of “Moderate Buy” and a consensus target price of $205.33.

Astrazeneca Stock Performance

Astrazeneca stock opened at $182.48 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. Astrazeneca Plc has a 12 month low of $137.23 and a 12 month high of $212.71. The company has a fifty day moving average price of $189.75 and a two-hundred day moving average price of $185.85. The company has a market cap of $283.00 billion, a PE ratio of 27.40, a P/E/G ratio of 1.56 and a beta of 0.25.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The company had revenue of $15.29 billion for the quarter, compared to the consensus estimate of $14.93 billion. Research analysts expect that Astrazeneca Plc will post 9.37 earnings per share for the current year.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.